Edoxaban Versus Low-Molecular-Weight Heparin in Hospitalized COVID-19 Patients With Atrial Fibrillation.

Pável Olivera,César Velásquez-Escandón,Desirée Campoy,Katia Flores,Tania Canals,Erik Johansson, María José Herranz,Laia Martínez,Juan José Cerezo-Manchado,Ramón Salinas

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS（2023）

引用 2|浏览0

暂无评分

摘要

Mortality rates, arterial and venous thromboembolic complications, and bleeds did not significantly differ between AF patients receiving anticoagulation therapy with edoxaban or LMWH followed by oral anticoagulation. However, the duration of hospitalization was significantly lower with edoxaban. Edoxaban had a similar therapeutic profile to LMWH followed by oral anticoagulation and may provide additional benefits.

查看译文

关键词

atrial fibrillation,COVID-19,edoxaban,low-molecular-weight heparin

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要